摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(3-benzyloxyphenyl)-cyclopropane-1,1-dicarboxylic acid dimethyl ester | 856432-30-9

中文名称
——
中文别名
——
英文名称
2-(3-benzyloxyphenyl)-cyclopropane-1,1-dicarboxylic acid dimethyl ester
英文别名
dimethyl 2-(3-phenylmethoxyphenyl)cyclopropane-1,1-dicarboxylate
2-(3-benzyloxyphenyl)-cyclopropane-1,1-dicarboxylic acid dimethyl ester化学式
CAS
856432-30-9
化学式
C20H20O5
mdl
——
分子量
340.376
InChiKey
ICGBHMQNOKSYHP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    25
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    61.8
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    dimethyl 2-(3-benzyloxybenzylidene)malonate 在 sodium hydride 作用下, 以 二甲基亚砜 为溶剂, 反应 1.5h, 以79%的产率得到2-(3-benzyloxyphenyl)-cyclopropane-1,1-dicarboxylic acid dimethyl ester
    参考文献:
    名称:
    [EN] CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    [FR] COMPOSES DE CYCLOPROPANE ET UTILISATION PHARMACEUTIQUE DE CEUX-CI
    摘要:
    公开号:
    WO2005058884A3
点击查看最新优质反应信息

文献信息

  • [EN] N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] COMPOSES DE N-SULFONYLAMINOCYCLOPROPANE N-SUBSTITUE ET LEUR UTILISATION PHARMACEUTIQUE
    申请人:JAPAN TOBACCO INC
    公开号:WO2005058808A1
    公开(公告)日:2005-06-30
    The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1) : wherein R1 is -W-A1-W1-A2, W is (CH2)m-X-(CH2)n-, wherein W1 is -(CH2)m1-X1-(CH2)n1-, m, m1, n and n1 are the same or different and each is 0 to 6, X and X1 are the same or different and each is a single bond, etc., A1 is an optionally substituted C3-14 hydrocarbon ring group, etc. and A2 is a substituted C3-14 hydrocarbon ring group etc.; R2 is -(CH2)r-CO-R8, etc., wherein r is 0 to 6 and R8 is a C1-6 alkoxy group, etc.; R3 and R4 are the same or different and each is a hydrogen atom, a C1-6 alkyl group, etc.; and R5 is -CO2R21, etc.; R30 and R31 are the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有减少聚集素酶活性和MMP-13抑制活性的化合物,并且可用作治疗骨关节炎、类风湿性关节炎等疾病的治疗剂,更具体地说,是一种具有如下结构的N-取代-N-磺酰环丙烷化合物(式1):其中R1为-W-A1-W1-A2,W为(CH2)m-X-( )n-,其中W1为-( )m1-X1-( )n1-,m、m1、n和n1相同或不同,且每个为0至6,X和X1相同或不同,且每个为单键,A1为可选择取代的C3-14碳氢环基团,等等,A2为取代的C3-14碳氢环基团等;R2为-( )r-CO-R8,等等,其中r为0至6,R8为C1-6烷氧基团,等等;R3和R4相同或不同,每个为氢原子、C1-6烷基基团,等等;R5为-CO2R21,等等;R30和R31相同或不同,每个为氢原子,等等;或其前药或其药学上可接受的盐。
  • Cyclopropane compounds and pharmaceutical use thereof
    申请人:Inaba Takashi
    公开号:US20060199826A1
    公开(公告)日:2006-09-07
    The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R 1 is —(CH 2 ) m —X—(CH 2 ) n -A 1 etc., wherein m and n are the same or different and each is 0 to 6, X 1 is a single bond, etc. and A 1 is a substituted C 3-14 hydrocarbon ring group, etc.; R 2 and R 3 are the same or different and each is a hydrogen atom, —(CH 2 ) p —X 1 -(CH 2 ) q -A 2 , etc., wherein p and q are the same or different and each is 0 to 6, X 1 is a single bond, etc. and A 2 is an optionally substituted C 3-14 hydrocarbon ring group, etc.; R 4 is —CO 2 R 9 , etc., wherein R 9 is a hydrogen atom, etc.; and R 20 and R 21 are the same or different and each is a hydrogen atom, —(CH 2 ) m12 —X 12 —(CH 2 ) m12 —R 30 , etc., wherein m12 and m12 are the same or different and each is 0 to 6, X 12 is a single bond, etc. and R 30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有抗软骨素酶活性和MMP-13抑制活性的化合物,可用作治疗骨关节炎、类风湿性关节炎等疾病的治疗剂,更具体地,是一种环丙烷化合物,其化学式为(1):其中,R1为—(CH2)m—X—( )n-A1等,其中m和n相同或不同,且每个为0至6,X1为单键等,A1为取代的C3-14碳氢环基等;R2和R3相同或不同,且每个为氢原子,—( )p—X1-( )q-A2等,其中p和q相同或不同,且每个为0至6,X1为单键等,A2为可选取代的C3-14碳氢环基等;R4为—CO2R9等,其中R9为氢原子等;且R20和R21相同或不同,且每个为氢原子,—( )m12—X12—( )m12—R30等,其中m12和m12相同或不同,且每个为0至6,X12为单键等,R30为氢原子等;或其前药或其药学上可接受的盐。
  • N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
    申请人:Fryer M. Andrew
    公开号:US20050222146A1
    公开(公告)日:2005-10-06
    The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1): wherein R 1 is —W-A 1 —W 1 -A 2 , W is —(CH 2 ) m —X—(CH 2 ) n —, wherein W 1 is —(CH 2 ) m1 —X 1 —(CH 2 ) n1 —, m, m1, n and n1 are the same or different and each is 0 to 6, X and X 1 are the same or different and each is a single bond, etc., A 1 is an optionally substituted C 3-14 hydrocarbon ring group, etc. and A 2 is a substituted C 3-14 hydrocarbon ring group etc.; R 2 is —(CH 2 ) r —CO—R 8 , etc., wherein r is 0 to 6 and R 8 is a C 1-6 alkoxy group, etc.; R 3 and R 4 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, etc.; and R 5 is —CO 2 R 21 etc.; R 30 and R 31 are the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有抑制聚集素酶活性和MMP-13抑制活性的化合物,可用作治疗骨关节炎、类风湿性关节炎等疾病的治疗剂,更具体地说,是式(1)的N-取代-N-磺酰基环丙烷化合物: 其中,R1为—W-A1—W1-A2,W为—(CH2)m—X—( )n—,其中W1为—( )m1—X1—( )n1—,m、m1、n和n1相同或不同,每个为0到6,X和X1相同或不同,每个为单键等;A1为可选取代的C3-14碳氢环基等,A2为取代的C3-14碳氢环基等;R2为—( )r—CO—R8等,其中r为0到6,R8为C1-6烷氧基等;R3和R4相同或不同,每个为氢原子、C1-6烷基等;R5为—CO2R21等;R30和R31相同或不同,每个为氢原子等;或其前药或药学上可接受的盐。
  • N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof
    申请人:Fryer Andrew M.
    公开号:US20080242656A1
    公开(公告)日:2008-10-02
    The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-N-sulfonylaminocyclopropane compound of formula (1) wherein R 1 is —W-A 1 -W 1 -A 2 , W is —(CH 2 ) m —X—(CH 2 ) n —, wherein W 1 is —(CH 2 ) m1 —X 1 —(CH 2 ) n1 —, m, m1, n and n1 are the same or different and each is 0 to 6, X and X 1 are the same or different and each is a single bond, etc., A 1 is an optionally substituted C 3-14 hydrocarbon ring group, etc. and A 2 is a substituted C 3-14 hydrocarbon ring group etc.; R 2 is —(CH 2 ) r —CO—R 8 , etc., wherein r is 0 to 6 and R 8 is a C 1-6 alkoxy group, etc.; R 3 and R 4 are the same or different and each is a hydrogen atom, a C 1-6 alkyl group, etc.; and R 5 is —CO 2 R 21 , etc.; R 30 and R 31 are the same or different and each is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有抑制聚集素酶和MMP-13的抑制活性,并且作为治疗骨关节炎、类风湿性关节炎等疾病的治疗剂的化合物,更具体地,是公式(1)中的N-取代-N-磺酰基环丙烷化合物,其中R1为—W-A1-W1-A2,W为—(CH2)m—X—( )n—,其中W1为—( )m1—X1—( )n1—,m,m1,n和n1相同或不同,每个为0至6,X和X1相同或不同,每个为单键,等等,A1为可选取代的C3-14碳氢环基等,A2为取代的C3-14碳氢环基等;R2为—( )r—CO—R8等,其中r为0至6,R8为C1-6烷氧基等;R3和R4相同或不同,每个为氢原子、C1-6烷基等;R5为—CO2R21等;R30和R31相同或不同,每个为氢原子等;或其前药或药学上可接受的盐。
  • CYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF
    申请人:INABA Takashi
    公开号:US20080261994A1
    公开(公告)日:2008-10-23
    The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein R 1 is —(CH 2 ) m —X—(CH 2 ) n -A 1 etc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and A 1 is a substituted C 3-14 hydrocarbon ring group, etc.; R 2 and R 3 are the same or different and each is a hydrogen atom, —(CH 2 ) p —X 1 —(CH 2 ) q -A 2 , etc., wherein p and q are the same or different and each is 0 to 6, X 1 is a single bond, etc. and A 2 is an optionally substituted C 3-14 hydrocarbon ring group, etc.; R 4 is —CO 2 R 9 , etc., wherein R 9 is a hydrogen atom, etc.; and R 20 and R 21 are the same or different and each is a hydrogen atom, —(CH 2 ) m12 —X 12 —(CH 2 ) m12 —R 30 , etc., wherein m12 and m12 are the same or different and each is 0 to 6, X 12 is a single bond, etc. and R 30 is a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.
    本发明提供了一种具有抑制aggrecanase和MMP-13活性的化合物,可用作治疗骨关节炎,类风湿性关节炎等疾病的治疗剂,更具体地说,是式(1)的环丙烷化合物:其中,R1为—(CH2)m—X—( )n-A1等,其中m和n相同或不同,每个为0至6,X为单键等,A1为取代的C3-14烃环基等;R2和R3相同或不同,每个为氢原子,—( )p—X1—( )q-A2等,其中p和q相同或不同,每个为0至6,X1为单键等,A2为可选取代的C3-14烃环基等;R4为—CO2R9等,其中R9为氢原子等;以及R20和R21相同或不同,每个为氢原子,—( )m12—X12—( )m12—R30等,其中m12和m12相同或不同,每个为0至6,X12为单键等,R30为氢原子等;或其前药或其药学上可接受的盐。
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯